Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

Stopped early · Not applicable

Conditions studied: Papillary Thyroid Cancer

In brief

We assess the effectiveness of percutaneous ethanol ablation for the treatment of thyroid cancer.

Key facts

Study ID

NCT01974284

Run by

Yale University

People needed

7

Starts

2014-03-01

Expected to finish

2017-06-29

Last updated by the study team

2019-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years and older
• Diagnosis: single, cytology-proven papillary thyroid carcinoma measuring 1 cm or less in diameter (microcarcinoma, T1a), without visible extrathyroidal extension, and with negative central and lateral neck lymph nodes by ultrasound

You may not qualify if…

• Patient refusal to participate
• History of prior thyroid or parathyroid surgery
• Previous recurrent laryngeal nerve injury
• Inability to make decisions or comply with follow up
• Co-existing indication for thyroidectomy
• Aggressive cytological or molecular features
• Multifocal papillary thyroid carcinoma
• Pregnant or breast-feeding
• Anatomically unfavorable location of the tumor (proximity to recurrent laryngeal nerve or trachea)
• Documented or suspected distant metastasis
• History of radiation to neck or face
• Family history of thyroid cancer

Where it is running

• Endocrine Surgery Smilow Cancer Hospital at Yale-New Haven — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.